First centralised OTC switch launched across EU
This article was originally published in SRA
Executive Summary
The anti-obesity drug, alli (orlistat 60mg), the first-ever centrally authorised medicine in the European Union to have its status switched from prescription-only to nonprescription, is now available as an over-the-counter product across the EU1,2. The change in the drug’s status could mark the start of a new trend in prescription-only to OTC switches.
You may also be interested in...
Global medtech alliance approves six new member associations
An emerging alliance of medical technology industry associations representing innovative companies that currently develop and manufacture 85% of the world's medical devices, diagnostics and equipment has approved the membership applications of six more associations, bringing the total number of members to 19.
Global medtech alliance approves six new member associations
An emerging alliance of medical technology industry associations representing innovative companies that currently develop and manufacture 85% of the world's medical devices, diagnostics and equipment has approved the membership applications of six more associations, bringing the total number of members to 19.
US FDA scrutiny of DTC genetic tests continues
The US FDA's devices unit has written to three genetic testing companies warning them that they may be marketing their products and services without clearance by the agency.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: